isoxazoles has been researched along with Androgen-Independent Prostatic Cancer in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Dar, JA; Eisermann, K; Feturi, FG; Johnston, PA; Kenefake, AN; Masoodi, KZ; Nelson, JB; Nguyen, M; O'Malley, K; Parrinello, E; Pascal, LE; Wang, Z; Wipf, P; Yang, Z | 1 |
| Chen, H; Ding, K; Dong, B; Li, C; Song, M; Wang, C; Wang, J; Wu, C; Wu, D; Wu, X; Xiang, Q; Xu, Y; Xue, W; Xue, X; Zhang, C; Zhang, M; Zhang, Y; Zhou, Y; Zou, L | 1 |
| Chen, H; Ding, K; Li, C; Li, G; Lu, Y; Wang, A; Wang, C; Wang, J; Wang, R; Wu, S; Xiang, Q; Xu, Y; Xue, X; Zhang, C; Zhang, M; Zhang, Y; Zou, L | 1 |
| Cronauer, M; Taubert, H; Wach, S | 1 |
| Butler, LM; Centenera, MM; Gillis, JL; Plymate, SR; Selth, LA; Sun, S; Tilley, WD; Townley, SL | 1 |
| Adelaiye, R; Ellis, L; Ku, S; Lasorsa, E; Pili, R; Ramakrishnan, S | 1 |
1 review(s) available for isoxazoles and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Role of androgen receptor splice variants, their clinical relevance and treatment options.
Topics: Alternative Splicing; Androgen Antagonists; Androstadienes; Antineoplastic Agents, Hormonal; Benzamides; Benzhydryl Compounds; Benzimidazoles; Benzoquinones; Binding Sites; Chlorohydrins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Isoindoles; Isoxazoles; Lactams, Macrocyclic; Male; Niclosamide; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein Domains; Protein Isoforms; Proteins; Receptors, Androgen; Resorcinols; RNA, Messenger | 2020 |
5 other study(ies) available for isoxazoles and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Inhibition of Androgen Receptor Function and Level in Castration-Resistant Prostate Cancer Cells by 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone.
Topics: Androgen Receptor Antagonists; Animals; Benzamides; Bexarotene; Binding Sites; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression; Humans; Isoxazoles; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Nitriles; Phenylthiohydantoin; Piperazines; Promoter Regions, Genetic; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Real-Time Polymerase Chain Reaction; Receptors, Androgen; Tetrahydronaphthalenes; Xenograft Model Antitumor Assays | 2017 |
Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC).
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Drug Design; Drug Discovery; Gene Expression Regulation, Neoplastic; Humans; Isoxazoles; Male; Mice; Models, Molecular; Nuclear Proteins; Prostatic Neoplasms, Castration-Resistant; Proteins; Structure-Activity Relationship; Substrate Specificity; Transcription Factors; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2018 |
Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer.
Topics: Animals; Antineoplastic Agents; Benzoxazines; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Isoxazoles; Male; Molecular Structure; Prostatic Neoplasms, Castration-Resistant; Proteins; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tumor Cells, Cultured | 2018 |
Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors.
Topics: Benzoquinones; Cell Line, Tumor; Cell Proliferation; Genetic Variation; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lactams, Macrocyclic; Male; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Resorcinols; Signal Transduction; Transcription, Genetic | 2013 |
Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; HSP90 Heat-Shock Proteins; Isoxazoles; Male; Mice; Mice, SCID; Prostatic Neoplasms, Castration-Resistant; Proteasome Endopeptidase Complex; Receptors, Androgen; Resorcinols; Taxoids; Transcription, Genetic; Transplantation, Heterologous | 2014 |